Effect of unnatural noradrenaline precursor on sympathetic control and orthostatic hypotension in dopamine-beta-hydroxylase deficiency
- PMID: 2890807
- DOI: 10.1016/s0140-6736(87)91318-3
Effect of unnatural noradrenaline precursor on sympathetic control and orthostatic hypotension in dopamine-beta-hydroxylase deficiency
Abstract
A patient with severe orthostatic hypotension due to dopamine-beta-hydroxylase deficiency was treated with the unnatural aminoacid D,L-threo-3,4-dihydroxyphenylserine (DOPS) in the hope that it would serve as a substrate of aromatic-L-aminoacid decarboxylase to produce (-)-noradrenaline. With a dose of 500 mg twice daily by mouth, blood pressure rose gradually from 100/55 to 145/85 mm Hg, and orthostatic hypotension disappeared. After 4 months' treatment the patient is free of symptoms and able to live a normal life. DOPS switched on the production of noradrenaline and reduced the excessive production of dopamine. During treatment plasma noradrenaline rose normally after standing and after infusion of tyramine, a biogenic amine that liberates stored neurotransmitter from sympathetic nerve terminals. These data demonstrate that in congenital dopamine-beta-hydroxylase deficiency dopamine instead of noradrenaline is released as the sympathetic neurotransmitter but that the integrity of the sympathetic neuron is otherwise intact.
Similar articles
-
d,l-threo-3,4-dihydroxyphenylserine restores sympathetic control and cures orthostatic hypotension in dopamine beta-hydroxylase deficiency.J Hypertens Suppl. 1988 Dec;6(4):S547-9. doi: 10.1097/00004872-198812040-00172. J Hypertens Suppl. 1988. PMID: 3149290
-
Endogenous restoration of noradrenaline by precursor therapy in dopamine-beta-hydroxylase deficiency.Lancet. 1987 Nov 21;2(8569):1170-2. doi: 10.1016/s0140-6736(87)91317-1. Lancet. 1987. PMID: 2890806 Clinical Trial.
-
Total norepinephrine spillover, muscle sympathetic nerve activity and heart-rate spectral analysis in a patient with dopamine beta-hydroxylase deficiency.J Auton Nerv Syst. 1995 Nov 6;55(3):198-206. doi: 10.1016/0165-1838(95)00048-3. J Auton Nerv Syst. 1995. PMID: 8801271
-
Clinical presentation and long-term follow-up of dopamine beta hydroxylase deficiency.J Inherit Metab Dis. 2021 May;44(3):554-565. doi: 10.1002/jimd.12321. Epub 2020 Oct 15. J Inherit Metab Dis. 2021. PMID: 33034372 Free PMC article. Review.
-
L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience.Clin Auton Res. 2008 Mar;18 Suppl 1:25-9. doi: 10.1007/s10286-007-1005-z. Epub 2008 Mar 27. Clin Auton Res. 2008. PMID: 18368304 Review.
Cited by
-
Neurogenic orthostatic hypotension - management update and role of droxidopa.Ther Clin Risk Manag. 2015 Jun 8;11:915-23. doi: 10.2147/TCRM.S68439. eCollection 2015. Ther Clin Risk Manag. 2015. PMID: 26089676 Free PMC article.
-
L-threo-3,4-dihydroxyphenylserine, a noradrenaline precursor, inhibits dopamine release and metabolism in the rat striatum in vivo.Experientia. 1992 Dec 1;48(11-12):1133-4. doi: 10.1007/BF01948006. Experientia. 1992. PMID: 1473578
-
Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson's disease: guideline "Parkinson's disease" of the German Society of Neurology.J Neurol. 2025 Jan 3;272(1):90. doi: 10.1007/s00415-024-12730-5. J Neurol. 2025. PMID: 39751950 Free PMC article. Review.
-
Droxidopa in neurogenic orthostatic hypotension.Expert Rev Cardiovasc Ther. 2015;13(8):875-91. doi: 10.1586/14779072.2015.1057504. Epub 2015 Jun 19. Expert Rev Cardiovasc Ther. 2015. PMID: 26092297 Free PMC article.
-
Update on the theory and management of orthostatic intolerance and related syndromes in adolescents and children.Expert Rev Cardiovasc Ther. 2012 Nov;10(11):1387-99. doi: 10.1586/erc.12.139. Expert Rev Cardiovasc Ther. 2012. PMID: 23244360 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources